Literature DB >> 12598231

Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin.

Ahmed A K Hasan1, Mark Warnock, Marvin Nieman, Sujata Srikanth, Fakhri Mahdi, Raman Krishnan, Alexander Tulinsky, Alvin H Schmaier.   

Abstract

Investigations determined the mechanism(s) by which Arg-Pro-Pro-Gly-Phe (RPPGF) inhibits thrombin-induced platelet activation. High concentrations of RPPGF inhibit thrombin-induced coagulant activity. RPPGF binds to the active site of thrombin by forming a parallel beta-strand with Ser214-Gly216 and interacts with His57, Asp189, and Ser195 of the catalytic triad. RPPGF competitively inhibits alpha-thrombin from hydrolyzing Sar-Pro-Arg-paranitroanilide with a Ki = 1.75 +/- 0.03 mM. Other mechanisms were sought to explain why RPPGF inhibits thrombin activation of platelets at concentrations below that which inhibits its active site. Soluble RPPGF blocks biotinylated NATLDPRSFLLR of the thrombin cleavage site on protease-activated receptor (PAR)1 from binding to the peptide RPPGC (IC50 = 20 microM). The soluble recombinant extracellular domain of PAR1 (rPAR1EC) blocks biotinylated RPPGF binding to rPAR1EC (IC50 = 50 microM) bound to microtiter plates, but rPAR1EC deletion mutants missing the sequence LDPR or PRSF do not. RPPGF and related forms prevent the thrombin-like enzyme thrombocytin from proteolyzing rPAR1EC at concentrations that do not block thrombocytin's active site. These studies indicate that RPPGF is a bifunctional inhibitor of thrombin: it binds to PAR1 to prevent thrombin cleavage at Arg41 and interacts with the active site of alpha-thrombin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598231     DOI: 10.1152/ajpheart.00490.2002

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  8 in total

1.  Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Authors:  M T Nieman; F Burke; M Warnock; Y Zhou; J Sweigart; A Chen; D Ricketts; B R Lucchesi; Z Chen; E Di Cera; J Hilfinger; J S Kim; H I Mosberg; A H Schmaier
Journal:  J Thromb Haemost       Date:  2008-02-25       Impact factor: 5.824

2.  Physiologic activities of the contact activation system.

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

3.  Oral thrombostatin FM19 inhibits prostate cancer.

Authors:  Marvin T Nieman; Gretchen LaRusch; Chao Fang; Yihua Zhou; Alvin H Schmaier
Journal:  Thromb Haemost       Date:  2010-09-30       Impact factor: 5.249

4.  Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.

Authors:  Chao Fang; Evi Stavrou; Alec A Schmaier; Nadja Grobe; Mariana Morris; Andrew Chen; Marvin T Nieman; Gregory N Adams; Gretchen LaRusch; Yihua Zhou; Matthew L Bilodeau; Fakhri Mahdi; Mark Warnock; Alvin H Schmaier
Journal:  Blood       Date:  2013-02-05       Impact factor: 22.113

5.  Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.

Authors:  Annis M Marney; Ji Ma; James M Luther; T Alp Ikizler; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

6.  Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Mark Warnock; Jonathon W Homeister; Sujata Srikanth; Yelena Krijanovski; Laine J Murphey; Ayad A Jaffa; Alvin H Schmaier
Journal:  Blood       Date:  2006-03-02       Impact factor: 22.113

7.  Thrombin mediates vagal apoptosis and dysfunction in inflammatory bowel disease.

Authors:  Danielle Fritze; Weizhen Zhang; Ji-Yao Li; Biaoxin Chai; Michael Mulholland
Journal:  J Gastrointest Surg       Date:  2014-06-11       Impact factor: 3.452

8.  Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells.

Authors:  Sheila Siqueira Andrade; Joana Tomomi Sumikawa; Eloísa Dognani Castro; Fabricio Pereira Batista; Edgar Paredes-Gamero; Lilian Carolina Oliveira; Izabel Monastério Guerra; Giovani Bravin Peres; Renan Pelluzzi Cavalheiro; Luiz Juliano; Afonso Pinto Nazário; Gil Facina; Siu Mui Tsai; Maria Luiza Vilela Oliva; Manoel João Batista Castello Girão
Journal:  Oncotarget       Date:  2017-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.